Another randomized phase III trial (NOAH trial) compared neoadjuvant chemotherapy plus trastuzumab, followed by 1 year of trastuzumab, with neoadjuvant chemotherapy alone in patients with locally advanced or inflammatory HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.